alcohol dehydrogenase Inhibitors
2 drugsAbout alcohol dehydrogenase
Alcohol dehydrogenase (ADH) is an enzyme crucial for alcohol metabolism, catalyzing the oxidation of alcohols to aldehydes or ketones. It plays a significant role in the breakdown of alcohol in the body.
Currently, there is no genetic evidence directly linking ADH to specific diseases. However, its role in alcohol metabolism makes it a relevant target for drug development.
Two FDA-approved drugs, MULTRYS and TRALEMENT, target alcohol dehydrogenase. Both drugs are small molecules developed by AM REGENT and were approved in 2020.
Top alcohol dehydrogenase Drugs
AM REGENT is the only company with approved drugs targeting alcohol dehydrogenase.
The market is highly concentrated, suggesting high barriers to entry for new competitors.
alcohol dehydrogenase Drug Modality Landscape
Modalities
Routes of Administration
alcohol dehydrogenase is druggable by small molecules, though no oral formulations are currently approved.
Exploring alternative modalities like antibodies could provide a competitive advantage.
alcohol dehydrogenase Clinical Trials 32 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on alcohol dehydrogenase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 | 100% |
| Phase 2 | 10 | 8 | 0 | 2 | 100% |
| Phase 3 | 8 | 6 | 0 | 2 | 100% |
| Phase 4 | 11 | 8 | 2 | 1 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
alcohol dehydrogenase Drug Approval Timeline (2020 - 2020)
The first and most recent drug approvals for this target occurred in 2020.
Recent approvals suggest renewed interest, but further approvals may indicate market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 27 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on alcohol dehydrogenase. A trial counts if an approved drug acting on alcohol dehydrogenase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.